
    
      Phase 2, randomized, placebo-controlled, parallel group, study in up to 62 adult patients
      with moderate to severe CCh. Eligible patients will be randomly assigned in a 1:1 ratio to
      one of two treatment groups, LO2A or placebo, stratified by LIPCOF grade at baseline.

      This study with 4 visits, will consist of a screening period of up to 2 weeks and a 3-month
      treatment period (topical, OU, QID application of eye drops).
    
  